Loading clinical trials...
Loading clinical trials...
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Conditions
Interventions
TNX-102 SL Tablet, 2.8 mg
Placebo SL Tablet
Locations
32
United States
Birmingham, Alabama, United States
Phoenix, Arizona, United States
Oceanside, California, United States
San Diego, California, United States
Brandon, Florida, United States
DeLand, Florida, United States
Start Date
July 22, 2016
Primary Completion Date
September 13, 2016
Completion Date
September 13, 2016
Last Updated
February 25, 2025
NCT06672237
NCT05901259
NCT03759522
NCT07398417
NCT07230171
NCT06084026
Lead Sponsor
Tonix Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions